

FOR INFORMATION

Nicox Announces Presentations at Upcoming Scientific Conferences

Nicox to present at major ophthalmology conferences including AGS (American Glaucoma Society) and ARVO (Association for Research in Vision and Ophthalmology) 2019

March 12, 2019
Sophia Antipolis, France

Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today announced a number of presentations of data at scientific conferences.

Details of the presentations (all times PST):

AGS 2019 Annual Meeting – March 14-17, 2019, San Francisco, U.S.

Poster title: Preclinical Evaluation of NCX 4251, A Novel Steroid Therapy For Blepharitis, Targeted Directly To The Eyelid Margin To Reduce The Potential For IOP Elevations

Type: Poster session

Date: March 15, 2019 - 7:00 am to 5:00 pm

Presenter: Dr. Robert Fechtner, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY

ARVO 2019 Annual Meeting –April 28-May 2, 2019, Vancouver, Canada

(UNDER EMBARGO PER ARVO POLICY UNTIL 10:30 PM CET ON APRIL 30)

Poster Title: Nonclinical development of NCX 470, a novel nitric oxide (NO)-donating, IOP lowering prostaglandin analog for glaucoma and ocular hypertension

Type: Poster Session

Session Title: Pharmacologic Interventions and Cellular Mechanisms

Date: April 30, 2019 from 11:45 am to 1:30 pm

Presenter: Elena Bastia, PhD, Nicox Research Institute

Poster Title: Concomitant dosing of the NO-donor NCX 667 (1%) and Xalatan® (latanoprost ophthalmic solution 0.005%) results in robust and sustained IOP-lowering in ocular normotensive dogs

Type: Poster Session

Session Title: Aqueous humor Dynamics and IOP

Date: April 30, 2019 from 8:45 am to 10:30 am

Presenter: Michael Bergamini, PhD, Chief Scientific Advisor, Nicox Ophthalmics, Inc.

Abstract Title: NCX 1741, a novel NO-donating derivative of the phosphodiesterase-5 inhibitor avanafil, reduces IOP in models of ocular hypertension and glaucoma

Type: Poster Session

Session Title: Pharmacologic Interventions and Cellular Mechanisms

Date: April 30, 2019 from 11:45 am to 1:30 pm

Presenter: Francesco Impagnatiello, PhD, Nicox Research Institute

Poster Title: Preclinical Evaluation of NCX 4251, a Novel Steroid Therapy for Blepharitis, Targeted Directly to the Eyelid Margin to Reduce the Potential for IOP Elevations

Type: Poster session

Session Title: Cornea Dry Eye Clinical Treatment

Date: May 2, 2019 from 10:15 am to 12:00 pm

Presenter: Tomas Navratil, PhD, Nicox Ophthalmics, Inc.

About Nicox

Nicox S.A. is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. By leveraging our proprietary expertise in nitric oxide (NO) donation and other technologies, we are developing an extensive portfolio of novel product candidates that target multiple ophthalmic conditions, including glaucoma. Our portfolio includes three programs in development including NCX 470 for intraocular pressure lowering, based on our proprietary NO-donating research platform and NCX 4251, a proprietary formulation of the well-established molecule fluticasone, for acute exacerbations of blepharitis. Our research activities are focused on novel future generation NO-donors including NO-donating phosphodiesterase-5 (PDE5) inhibitors and NO-donating soluble guanylate cyclase (sGC) stimulators (in partnership with Ironwood). In addition, we have two ophthalmology assets that have been approved by the U.S. Food and Drug Administration (FDA); VYZULTA® (latanoprostene bunod ophthalmic solution), 0.024%, exclusively licensed worldwide to Bausch + Lomb, a Bausch Health Companies Inc. company, and commercialized in the U.S. by Bausch + Lomb since December 2017, as well as ZERVIATE™ (cetirizine ophthalmic solution), 0.24%, exclusively licensed in the U.S. to Eyeavance Pharmaceuticals. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com

Analyst coverage

Bryan, Garnier & Co Hugo Solvet Paris, France
H.C. Wainwright & Co Yi Chen New York, U.S.



The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.

Upcoming financial and business conferences

March 11-13	Cowen 39 th Annual Health Care Conference	Boston, U.S.
March 19-20	Oppenheimer's 29th Annual healthcare Conference	New York, U.S.
April 7-9	H.C. Wainwright Global Life Sciences Conference	London, UK
April 16-17	SmallCap Event	Paris, France
May 16	European MidCap Event	Copenhagen, Denmark
June 2-6	BIO 2019	Philadelphia; U.S.
June 18-19	European MidCap Event	Paris, France

Contacts

Nicox

Gavin Spencer,
Executive Vice President, Chief Business Officer
Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investors & Media
United States & Europe
LifeSci Advisors, LLC
Hans Herklots
T +41 79 598 71 49
hherklots@lifesciadvisors.com

Media
France
LifeSci Advisors, LLC
Sophie Baumont
M +33 (0)6 27 74 74 49
sophie@lifesciadvisors.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox's business are presented in the 4th chapter of the '*Document de référence, rapport financier annuel et rapport de gestion 2018*' filed with the French *Autorité des Marchés Financiers* (AMF) on March 6, 2019, which are available on Nicox's website (www.nicox.com).

Nicox S.A.

Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99